5Bailie GR,Johnson CA,Mason NA.Parenteral iron use in the management of anemia in end-stage renal disease patients.Am J Kid Dis,2000,35(1):1-12
6Kumpf VJ.Parenteral iron supplementation.Nutr Clin Pract,1996,11(4):139-46
7Sloand JA,Shelly MA,Feigin A,et al.A double-blind,placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome.Am J Kidney Dis,2004,43(4):663-670
8Fishbane S,Ungureanu V,Macsaka JK,et al.Safety of intravenous iron dextran in hemodialysis patients.Am J Kidney Dis,1996,28(4):529-534
二级参考文献17
1Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis [J]. Am J Kidney Dis, 1996, 27:234-238
2de Francisco AL, Fernandez FG, Rodrigo E, et al. Past,present and future of erythropoietin use in the elderly[J]. Iht Urol Nephrol, 2002, 33:187-193
3Kato A, Hamada M, Suzuki T, et al. Effect of weekly or successive iron supplementation on erythropoietin doses in patients receiving hemodialysis [J]. Nephron, 2001, 89:110-112
4Peacodk E, lindenfeld SM. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients [J]. ANNA J, 1999, 26:337-343
5Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation [J]. Am J Kidney Dis, 1995,26(1):41-46
6Dittrich E, Schillinger M, Sunder-Plassmann G, et al.Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients [J]. Perit Dial Int, 2002,22:60-66
7Silverberg DS, Blum M, Agbaria Z, et al. Intravenous iron for the treatment of predialysis anemia [J]. Kidney Int Suppl, 1999, 69:S79-S85
8Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study [J]. J Am Soc Nephrol, 1998, 9:664-668
9Sloand JA, Shelly MA, Erenstone AL, et al. Safety and efficacy of total dose iron dextran administration in patients on home renal replacement therapies [J]. Perit Dial Int, 1998, 18:522-527
10Sepandj F, Jindal K, West M, et al. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients [J]. Nephrol Dial Transplant, 1996, 11:319-322
2[1]National Kidney Foundation-Dialysis Outcomes Quality Initiative.NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure[J].Am J Kidney Dis,1997,30(4 Suppl 3):S192～S240.
3[2]National Kidney Fundation.K/DOQI Clinical Practice Guide-lines:Anemia of chronic Kidney Disease update 2000[J].AmJ Kidney Dis,2001,(Suppl 1)37:S182～S238.
4[3]Manley HJ,Grabe DW.Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis:an invitro study[J].BMC Nephrol,2004,12(5):1.
5[4]S1oand JA,Shelly MA,Feigin A,et al.A doubleblind,placebo controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome[J].Am J Kidney Dis,2004,43(4):663～670.
6[6]Reis KA,Guz G,Ozdemir H,et al.Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease[J].Int Heart J,2005,46(2):255～264.
